| Literature DB >> 24454384 |
Saad Musbah Alasil1, Rahmat Omar2, Salmah Ismail3, Mohd Yasim Yusof4, Ghulam N Dhabaan4, Mahmood Ameen Abdulla5.
Abstract
Diseases of the tonsils are becoming more resistant to antibiotics due to the persistence of bacteria through the formation of biofilms. Therefore, understanding the microbiology and pathophysiology of such diseases represent an important step in the management of biofilm-related infections. We have isolated the microorganisms, evaluated their antimicrobial susceptibility, and detected the presence of bacterial biofilms in tonsillar specimens in correlation with the clinical manifestations ofEntities:
Year: 2013 PMID: 24454384 PMCID: PMC3886491 DOI: 10.1155/2013/408238
Source DB: PubMed Journal: Int J Otolaryngol ISSN: 1687-9201
Association between the clinical symptoms of tonsillar diseases and the presence of biofilms in tonsils.
| Clinical symptom | Patients with clinical symptom | Patients with evidence of biofilm |
|---|---|---|
| (1) Tonsillar hypertrophy | 49 (70%)* | 42 (60%)* |
| (2) Sore throat | 40 (57%)* | 40 (57%)* |
| (3) Adenoid hypertrophy | 26 (37.14%)* | 13 (18%)* |
| (4) Apnea | 12 (17.14%)* | 10 (14%)* |
| (5) Nasal obstruction | 12 (17.14%)* | 10 (14%)* |
*Percentage was calculated based on the total number of patients which was 70.
Distribution of bacterial isolates among tonsillar specimens.
| Gram-positive isolates | Tonsillar biopsy (core) no. (%) | Tonsillar swab (surface) no. (%) | Total no. (%) |
|---|---|---|---|
|
| 85 (18.31%) | 99 (21.33%) | 184 (39.65%) |
|
| 36 (7.75%) | 20 (4.31%) | 56 (12.06%) |
| Group G streptococci | 11 (2.37%) | 14 (3.01%) | 25 (5.38%) |
|
| 6 (1.29%) | 8 (1.72%) | 14 (3.01%) |
| Group F streptococci | 5 (1.07%) | 6 (1.29%) | 11 (2.37%) |
| Group C streptococci | 4 (0.86%) | 4 (0.86%) | 8 (1.72%) |
|
| 1 (0.21%) | 2 (0.43%) | 3 (0.64%) |
| Methicillin resistant | 0 | 1 (0.21%) | 1 (0.21%) |
| Subtotal |
|
|
|
|
| |||
| Gram-negative isolates | Tonsillar biopsy (core) no. (%) | Tonsillar swab (surface) no. (%) | Total no. (%) |
|
| |||
|
| 44 (9.48%) | 42 (9.05%) | 86 (18.53%) |
|
| 10 (2.15%) | 21 (4.52%) | 31 (6.68%) |
|
| 15 (3.23%) | 15 (3.23%) | 30 (6.46%) |
|
| 5 (1.07%) | 4 (0.86%) | 9 (1.93%) |
|
| 2 (0.43%) | 2 (0.43%) | 4 (0.86%) |
|
| 1 (0.21%) | 0 | 1 (0.21%) |
|
| 0 | 1 (0.21%) | 1 (0.21%) |
| Subtotal |
|
|
|
| Total |
|
|
|
Figure 1Antimicrobial susceptibility of tonsillar isolates against selected β-lactam agents. AM: ampicillin, AMC: amoxicillin-Clavulanic acid, SAM: ampicillin-Sulbactam, CFP: cefoperazone, CTX: cefotaxime, CAZ: ceftazidime, CTR: ceftriaxone, CXM: cefuroxime, LEX: cephalexin, IPM: imipenem, ME: methicillin, PEN: penicillin, TZP: piperacillin-Tazobactam. (S) indicates susceptible isolates and (R) indicates resistant isolates.
Figure 2Antimicrobial susceptibility of tonsillar isolates against selected non-β-lactam agents. AN: amikacin, AZM: azithromycin, CM: clindamycin, CIP: ciprofloxacin, SXT: co-trimoxazole, EM: erythromycin, FA: fusidic Acid, GM: gentamicin, RA: rifampin, VA: vancomycin. (S) indicates susceptible isolates and (R) indicates resistant isolates.
Figure 3Microscopic evidence of bacterial biofilms on the tonsillar surface via SEM. (a) Overall image of biofilm from a patient with recurrent tonsillitis showing the layers of network-like glycocalyx (low magnification 1500x). (b) Representative image of biofilm from a patient with chronic tonsillitis showing bacterial cells attached to the surface of tonsillar cells and embedded in a network-like glycocalyx (high magnification 25000x). Arrows indicate the biofilm structures.
Figure 4Microscopic evidence of bacterial biofilms within the tonsillar crypts via CLSM. (a) Representative image of biofilm from a patient with obstructive sleep apnea showing bacterial cells (red) embedded with glycocalyx (green) surrounding the tonsillar nuclei (red). (b) Three-dimensional image of a biofilm showing bacterial aggregates (cells) embedded in a glycocalyx matrix (100x). Arrows indicate the biofilm structures and tissue sections were stained with propidium iodide and concanavalin A.